


# CLINICAL TRIAL

NCT03660917

Neuroophthalmology RED,  
Pediatric RED,  
Low vision, Research



## Riluzole in patients with spinocerebellar ataxia type 7: a randomized, double-blind, placebo-controlled pilot trial with a lead in phase

Rare Eye Disease concerned by the trial :  
Retinal dystrophy occurring as a feature  
of spinocerebellar ataxia type7

Status of the trial : Active, not recruiting

Orphan drug recognition : Yes

Inclusion criteria : Genotype confirmed spinocerebellar ataxia; at least 7 year old

Exclusion criteria : Serious systemic illnesses or conditions (cardiac, haematologic and hepatic diseases) known for enhancing the side effects of riluzole, pregnancy or breastfeeding.



Inclusion  
opening date : 01/07/2018



Inclusion closing  
date (previsional) : 01/02/2019

Children



Adults



### Within ERN-EYE members



Principal location of the trial :

**Department of Neuroscience, Mental  
Health and Sense Organs NESMOS**  
Sapienza University of Rome, S.Andrea  
Hospital  
Via di Grottarossa 1035,  
00189 Rome, Italy



Principal investigator name :

Giovanni Ristori




Other investigators :

Agnese Suppiej  
**Ospedaliera Universitaria Padova and University  
of Ferrara, Italy**

Gabriella Silvestri

**Policlinico A.Gemelli, Rome, Italy**



Funder type : National Institution

[More informations](#)